DBV TECHNOLOGIE/S (NASDAQ:DBVT) Rating Lowered to Sell at BidaskClub
Other analysts also recently issued reports about the stock. Zacks Investment Research raised shares of DBV TECHNOLOGIE/S from a hold rating to a buy rating and set a $9.75 price target for the company in a research note on Wednesday, June 12th. JMP Securities reissued a buy rating and issued a $20.00 price target on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Finally, Stifel Nicolaus reissued a hold rating and issued a $10.00 price target on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $14.75.
DBV TECHNOLOGIE/S stock opened at $8.03 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34. DBV TECHNOLOGIE/S has a twelve month low of $3.60 and a twelve month high of $25.77.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: What is a Call Option?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.